Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-ascending dose PK and safety of gadopiclenol in Japanese healthy volunteers
jRCT2071210029Phase 1Completed
- Sponsor
- Guerbet
- Start
- May 2021
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of gadopiclenol (4 arms), sponsored by Guerbet. Primary endpoints: Plasma pharmacokinetics of gadopiclenol and Urine pharmacokinetics of gadopiclenol. Started May 2021; status: completed.
02
Drugs
gadopiclenol
Beyond the preview
Go deeper on jRCT2071210029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210029.